contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-3006-scandinavian-medical-solutions-gubra-bioporto-columbus-flugger-og-aktier-med-friis

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Research

Kasper Lihn

CEO, Sweden

Claus Thestrup

Head of Equities

Michael Friis

Head of Research, Stables

Rasmus Køjborg

Scandinavian Medical Solutions is a Danish-based trading company specialized in purchase and resale of used diagnostic imaging equipment such as CT scanners and MR scanners of high quality. Scandinavian Medical Solutions is specialized in offering flexible solutions for customers with specific demands, which is often a better and cheaper alternative to a new and more expensive produced OEM-equipment.

Scandinavian Medical Solutions was founded in 2018, and the company has been listed at Nasdaq First North in Denmark since November 2021.

Scandinavian Medical Solutions

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Gubra

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel.

It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets. 

BioPorto

Flügger develops, produces, markets, and sells interior and exterior decorative paint, wood stains, filler, and tools; selling to professional painters, private customers, and builder’s merchants. Flügger originates from Denmark and is listed on the Nasdaq OMX Copenhagen Stock Exchange.

Flügger has a strong market position in the Nordic markets, where it is the market leader in Denmark. Its physical Flügger Farver stores are well known throughout the Nordic region and are the company’s primary sales channel; however, Flügger also has private label sales via builder’s merchants as well as developing e-commerce capabilities.

Flügger’s position in the Nordics is relatively stable, whereas the company has growth via export markets and its own presence in Eastern Europe, with a long history in Poland and by the acquisitions of Unicell and Eskaro.

Flügger Group

Columbus is an international consultancy headquartered in Denmark with more than 1,500 employees and 1,100 customers worldwide. Columbus delivers digital solutions supporting business-critical processes across industries such as Manufacturing, Retail, Food & Beverage, and Life Science. Services include Cloud Services, Data & AI, ERP, CRM, Digital Commerce, and Cybersecurity. Columbus has a local presence in the Nordics, the United Kingdom, and the United States – and global delivery – and is positioned to drive digital transformation and enable scalable growth. The company serves more than 1,100 customers worldwide.


Columbus

Dagens aktienyheder med Scandinavian Medical Solutions, Gubra, BioPorto, Columbus, Flügger og Aktier med Friis

Scandinavian Medical Solutions annoncerede i sidste uge to nye salg af henholdsvis en MRI-scanner til en amerikansk kunde i torsdags og en PET/CT-scanner til en kunde i Centraleuropa i fredags. Med disse salg har Scandinavian Medical Solutions annonceret nye aftaler til markedet (kun ordrer p&#xe5; over DKK 2 mio.) for mellem DKK 69,0-108,0 mio. i dette regnskabs&#xe5;r 2024/25 (1. oktober 2024 til i dag den 30. juni 2025). I samme periode i regnskabs&#xe5;ret 2023/24 (1. oktober 2023 til den 30. juni 2024) havde Scandinavian Medical Solutions offentliggjort ordrer til markedet p&#xe5; mellem DKK 60,0-95,0 mio. Vi kender dog ikke antallet og st&#xf8;rrelsen af de ikke-annoncerede aftaler, der har en v&#xe6;rdi p&#xe5; under DKK 2 mio.
I relation til Gubra blev det ekstraordin&#xe6;re udbytte godkendt p&#xe5; fredagens ekstraordin&#xe6;re generalforsamling. Aktien lukkede fredag med en stigning p&#xe5; +2,43% i kurs DKK 526. Aktien g&#xe5;r ex. udbytte i dag med DKK 61,2 pr. aktie og betaling ventes at ske til aktion&#xe6;rernes konto den 2. juli 2025.
BioPorto p&#xe5;begynder kommercialisering af ProNephro AKI (NGAL) til diagnostisk brug i USA &#x2013; l&#xe6;s mere her: <a href="https://www.inderes.dk/analyst-comments/bioporto-forste-ordre-fra-distributionspartneren-roche-diagnostics" target="_blank" rel="noopener">https://www.inderes.dk/analyst-comments/bioporto-forste-ordre-fra-distributionspartneren-roche-diagnostics</a>
Columbus igangs&#xe6;tter i dag et aktietilbagek&#xf8;bsprogram p&#xe5; DKK 16 mio., eller maksimalt 1,6 mio. aktier, svarende til ca. 1,2% af aktiekapitalen Programmet l&#xf8;ber indtil 11. marts 2026. l&#xe6;s mere her:&#xa0;<a href="https://www.inderes.dk/releases/columbus-launch-of-share-buyback-programme-under-the-safe-harbour-regulation" target="_blank" rel="noopener">https://www.inderes.dk/releases/columbus-launch-of-share-buyback-programme-under-the-safe-harbour-regulation</a> Husk at vi i dag kl. 12.00 afholder event med ledelsen i Fl&#xfc;gger i forl&#xe6;ngelse af selskabets &#xe5;rsregnskab for 2024/25, der blev offentliggjort i sidste uge. Tilmelding her: <a href="https://www.inderes.dk/videos/flugger-praesentation-af-arsregnskabet-202425">https://www.inderes.dk/videos/flugger-praesentation-af-arsregnskabet-202425</a>
I Aktier med Friis i fredags s&#xe5; ind p&#xe5; om vi er i gang med en melt-up i markedet lige nu, og om optimismen om rentes&#xe6;nkninger fra den amerikanske centralbank og optimisme om &#xf8;konomien kan forts&#xe6;tte med at skabe et lille goldilock scenario i markedet lige nu. Se afsnittet her: <a href="https://www.inderes.dk/videos/aktier-med-friis-uge-26-2025" target="_blank" rel="noopener">https://www.inderes.dk/videos/aktier-med-friis-uge-26-2025</a>
Disclaimer: HC Anderen Capital modtager betaling fra de n&#xe6;vnte selskaber for en digital IR/Corporate Visibility abonnementsaftale.
/Rasmus K&#xf8;jborg d. 30/06-2025 kl. 09:10.

HC Andersen Capital

Dagens aktienyheder 30/06: Scandinavian Medical Solutions, Gubra, BioPorto, Columbus, Flügger og Aktier med Friis

Stay up to date